PARIS — Beiersdorf AG is expanding its knowledge of the skin’s microbiome with the acquisition of S-Biomedic NV.

The German maker of Nivea, La Prairie and Tesa products said Friday that it has purchased a majority stake within the Belgian life-science company, which is touted as a pioneer in skin microbiome research field.

Financial terms of the deal weren’t disclosed.

In an announcement released Friday, Beiersdorf described the microbiome as offering “unique starting points for break-through skincare innovations.”

Over the past few years, beauty corporations have increasingly turned toward skin’s microbiome, where billions of bacteria live, as a key factor for skin health.

Their research and development has resulted within the creation of latest products made to assist balance the microbiome which, when it’s disrupted, can trigger skin conditions resembling pimples.

Beiersdorf has for years focused on the potential of treating the skin microbiome for skincare. It invested in S-Biomedic in 2018 as a part of its corporate enterprise capital activity.

Following the takeover, S-Biomedic will still be managed as a freestanding organization under Beiersdorf’s microbiome program. Beiersdorf said within the statement that S-Biomedic will complement its own research on this domain.

S-Biomedic was founded by Veronika Oudova and Bernhard Paetzold in 2014. The corporate researches and develops lively ingredients for cosmetics products using living skin bacteria.

“As skincare experts, research has been at the guts of what we’ve got been doing for 140 years. Due to this fact, the acquisition of S-Biomedic is a perfect strategic fit to drive our innovation power even further in step with our C.A.R.E.+ strategy,” said Gitta Neufang, senior vice chairman of research and development of Beiersdorf, within the statement.

She was referring to the group’s technique to win in skincare and boost consumer-centricity through digitization.

“Along with the pioneers of S-Biomedic, we’re taking skincare to the following level and can foster the event of solutions for unmet consumer needs,” Neufang said.

“The advances of S-Biomedic in biomedical research complement our own efforts on this field and open the door to develop products that work in harmony with the natural skin processes,” said Jörn Hendrik Reuter, manager microbiome accelerator at Beiersdorf.

Oudova, chief executive officer of S-Biomedic, added: “Our vision since 2014, after we began S-Biomedic, has been to construct and promote skin microbiome technologies and make them to the brand new frontier in skin health. I’m very excited that along with the team we’ve got achieved an important milestone on that journey. By joining Beiersdorf our novel approach has its path to consumers everywhere in the world.”